The quality of evidence is downgraded by imprecise result, inconsistency (heterogeneity of results across trials) and potential reporting bias (only few small trials reported).
A Cochrane review included 3 studies with a total of 470 subjects comparing human recombinant interleukin 10 to placebo for induction of remission in Crohn's disease.
There was no statistically significant difference in the number of complete remissions in patients that received interleukin 10 compared to placebo (79 events, 3 trials; RR 1.43; 95% CI 0.62 to 3.29). Serious adverse (99 events, 1 trial) events were more frequent in the IL-10 group compared to placebo, but the difference was not statistically significant (RR 1.13; 95 % CI 0.73 to 1.74)